ARTICLE | Clinical News
Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout
April 19, 2019 9:41 PM UTC
With the latest Phase III data for Pfizer and Lilly's tanezumab showing a long-term increase in the incidence of a safety concern that has dogged the anti-NGF mAb, the partners said late Thursday they now plan to review the totality of data from the tanezumab program with regulatory authorities to determine next steps.
High-dose tanezumab from Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY) hit two of the three co-primary efficacy endpoints compared with NSAIDs in patients with osteoarthritis of the knee or hip, while low-dose tanezumab missed all three...
BCIQ Target Profiles